Oncolytic Virus Therapy Market to grow with a CAGR of 22.92% through 2030
Increasing healthcare infrastructure and a supportive regulatory environment is expected to drive the Global Oncolytic Virus Therapy Market growth in the forecast period, 2026-2030.
According
to TechSci Research report, “Oncolytic Virus Therapy Market - Global Industry
Size, Share, Trends, Competition, Forecast & Opportunities, 2030”, Global Oncolytic Virus Therapy
Market has valued at USD 16.57 billion in 2024 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 22.92% in the forecast period, 2026-2030. This
can be due to collaborations and partnerships among leading companies with a
diverse approach to merge the expertise of individual companies and to
strengthen their position in the market.
The
presence of unmet medical needs within the field of cancer treatment is a
significant driver of the demand for oncolytic virus therapy. Oncolytic virus
therapy is often considered when patients have advanced or treatment-resistant
cancers that do not respond well to standard treatments, such as chemotherapy
or radiation therapy. This patient population represents a substantial unmet
need. For certain cancer types, especially those with limited treatment
options, oncolytic virus therapy offers a new and innovative approach. Patients
and healthcare providers turn to these therapies when conventional treatments
have been exhausted. Patients who experience cancer recurrence, where the
cancer returns after initial treatment, often face limited options.
Oncolytic
virus therapy may provide an alternative that can be effective against
recurrent tumors. Some cancers develop in anatomically challenging locations
where surgery or other interventions are difficult. It can be considered for
these cases. Pediatric cancers and rare cancers may have limited treatment
options due to their low prevalence. Oncolytic virus therapy can address unmet
needs in these specific patient populations. Older patients and those with
frail health may not be suitable candidates for aggressive treatments like
surgery or high-dose chemotherapy. Oncolytic virus therapy can be considered as
a more tolerable option for these individuals.
Immune
response and clearance represent a notable challenge in the global oncolytic
virus therapy market. The interaction between oncolytic viruses and the immune
system can have a significant impact on the safety and efficacy of these
therapies. The human immune system can recognize and respond to oncolytic
viruses, potentially leading to their clearance before they effectively target
and destroy cancer cells. Immune recognition can limit the therapeutic effect. The
host immune system may mount an antiviral immune response against the oncolytic
virus, preventing its replication and spread within the tumor. This immune
reaction can hinder the therapeutic outcome. Pre-existing neutralizing
antibodies in patients can render oncolytic viruses ineffective by blocking
their ability to infect and replicate within tumor cells. Even if oncolytic
viruses initially infect and replicate in tumor cells, the immune system can
eliminate the infected cells, limiting the treatment's effectiveness. The
immunosuppressive microenvironment within tumors can hamper the effectiveness
of oncolytic viruses by inhibiting the host immune response. Tumor cells may
release factors that suppress immune activity, allowing them to evade detection
and destruction.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
" Global Oncolytic Virus Therapy Market”
Global Oncolytic Virus Therapy Market is segmented based
on Virus Type, Application, End User, and by region.
Based on the Virus Type, Herpes Simplex Virus (HSV) shows the fastest growth over the forecast period. Herpes Simplex Virus (HSV) has been extensively studied and engineered for oncolytic purposes. It has demonstrated efficacy in targeting and destroying cancer cells. The robust body of research supporting HSV-based therapies may have contributed to its dominance. HSV-based oncolytic therapies were among the earliest to enter clinical trials and gain regulatory approval. Their history and experience in the field provide a foundation for their prominence. HSV-based therapies have been developed with a focus on safety, which is crucial for regulatory approval and clinical adoption. This safety profile can make them an attractive choice for patients and healthcare providers. Researchers have made significant advancements in genetically modifying HSV to enhance its tumor-targeting capabilities and reduce its impact on healthy cells. These modifications have improved the therapeutic potential of HSV-based oncolytic viruses.
Based on Region, the APAC (Asia-Pacific) region is experiencing significant growth in the Oncolytic Virus Therapy market. This growth is driven by an increasing focus on innovative cancer treatments, a rising demand for personalized therapies, and advancements in biotechnology. As the region's healthcare infrastructure improves and the prevalence of cancer continues to rise, there is greater investment in developing and adopting cutting-edge therapies like oncolytic virus treatments. Additionally, the region's expanding biotech sector, supportive regulatory environments, and growing collaboration between research institutions and pharmaceutical companies are further contributing to the market's rapid expansion in APAC.
Some
of the major companies operating in the Global
Oncolytic Virus Therapy Market include:
- Amgen
Inc.
- Merck
& Co., Inc.
- Oncolytics
Biotech Inc.
- PsiOxus
Therapeutics Ltd.
- Vyriad,
Inc.
- SillaJen
Biotherapeutics
- Cold
Genesys Inc.
- Sorrento
Therapeutics, Inc.
- Takara
Bio Inc.
- Replimune
Group Inc.
- Genelux
Corporation
Download Free Sample Report
Customers
can also request 10% free customization on this report
“Certain areas, particularly in North
America, are projected to exert significant demand for Oncolytic Virus Therapy.
The growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global Oncolytic
Virus Therapy Market in the forecast period," said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based Global management
consulting firm.
"Oncolytic Virus Therapy Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Virus Type (Adenovirus, Herpes Simplex Virus (HSV), Measles Virus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus (VSV), Others), By Application (Solid Tumors, Hematological Malignancies), by End User (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies), By Region & Competition 2020-2030F", has
evaluated the future growth potential of Global Oncolytic Virus Therapy
Market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide innovative market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Oncolytic Virus
Therapy Market.
Contact
Techsci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel:
+13322586602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com